TMEFF1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08893(TMEFF1 Antibody) at dilution 1/140. (Original magnification: ×200)    

  
  

**Background of TMEFF1 Antibody**

TMEFF1 (Transmembrane protein with EGF-like and two follistatin-like domains 1), also known as tomoregulin-1 or TR-1. is a glycosylated transmembrane protein belonging to the TMEFF family. It is characterized by an extracellular region containing an epidermal growth factor (EGF)-like domain and two follistatin-like domains, which are implicated in protein-protein interactions and modulation of signaling pathways. TMEFF1 is predominantly expressed in the brain, particularly in the hippocampus and cerebral cortex, and plays roles in neuronal development, differentiation, and maintenance of the central nervous system (CNS).

Research suggests TMEFF1 is involved in regulating growth factor signaling, including interactions with bone morphogenetic proteins (BMPs) and insulin-like growth factors (IGFs). Dysregulation of TMEFF1 has been linked to neurological disorders, such as Alzheimer’s disease, and certain cancers, including prostate cancer and glioblastoma, where its expression may serve as a biomarker or therapeutic target.

TMEFF1 antibodies are essential tools for detecting and studying the protein’s expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate TMEFF1’s role in physiological and pathological contexts. These antibodies, often monoclonal or polyclonal, require validation for specificity, typically via knockout controls or siRNA-mediated silencing. Ongoing studies aim to clarify TMEFF1’s dual roles in tumor suppression and oncogenesis, highlighting its potential in diagnostics and targeted therapies.